Pantoprazole
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Oral and Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 77% |
Metabolism | Hepatic |
Elimination half-life | 1 hour |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.111.005 |
Chemical and physical data | |
Formula | C16H15F2N3O4S |
Molar mass | 383.371 |
Pantoprazole (marketed under the brand names Protium, Protonix, Pantozol, "Pantor" and Pantoloc) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. Initial treatment is generally of eight weeks' duration, after which another eight week course of treatment may be considered if necessary. It can be used as a maintenance therapy for long term use after initial response is obtained.
Pharmacology
Pantoprazole is metabolized in the liver by the cytochrome P450 system. Metabolism mainly consists of demethylation by CYP2C19 followed by sulfation. Another metabolic pathway is oxidation by CYP3A4. Pantoprazole metabolites are not thought to have any pharmacological significance.
Availability
Pantoprazole was developed by Altana and is currently marketed under the brand name Protonix® by Wyeth-Ayerst Laboratories, Somac® by Pfizer "Pantor®" by Bosnalijek, and as Pantoloc® by Solvay Pharma and as Protium in the UK. It is available by prescription in controlled-release tablets. It is also available for intraveinous use. This is the only benzimidazole available in USA for use as injection. Other benzimidazoles like Omeprazole/ Esomeprazole are not available for I.V. use in USA.
External links
- Official Protonix Homepage
- Protonix Facts Information Sheet
- Pantoprazole
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.